Rhizen receives USFDA fast track designation for cancer drug

USFDA has granted Fast Track Designation for RP6530.. for the treatment of patients with relapsed/refractory peripheral T- cell lymphoma (PTCL)," Alembic Pharmaceuticals said in a BSE filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news